$CKPT
Checkpoint Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000141057824001885 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.358M
YoY Change 49.91%
% of Gross Profit
Research & Development $6.366M
YoY Change 15.83%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $9.724M
YoY Change 25.76%
Operating Profit -$9.724M
YoY Change 26.27%
Interest Expense -$1.000K
YoY Change -110.0%
% of Operating Profit
Other Income/Expense, Net -$1.000K
YoY Change -100.05%
Pretax Income -$9.725M
YoY Change 70.02%
Income Tax
% Of Pretax Income
Net Earnings -$9.725M
YoY Change 69.9%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23
Diluted Earnings Per Share -$0.23
COMMON SHARES
Basic Shares Outstanding 43.15M
Diluted Shares Outstanding 43.15M

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.703M
YoY Change 165.71%
Cash & Equivalents $4.703M
Short-Term Investments
Other Short-Term Assets $476.0K
YoY Change 1435.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.179M
YoY Change 133.5%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.179M
Total Long-Term Assets $0.00
Total Assets $5.179M
YoY Change 133.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.891M
YoY Change -0.83%
Accrued Expenses $1.102M
YoY Change 8.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.77M
YoY Change -16.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $17.77M
Total Long-Term Liabilities $0.00
Total Liabilities $17.77M
YoY Change -16.42%
SHAREHOLDERS EQUITY
Retained Earnings -$341.7M
YoY Change 15.75%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$12.59M
YoY Change
Total Liabilities & Shareholders Equity $5.179M
YoY Change 133.5%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$9.725M
YoY Change 69.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$11.21M
YoY Change -24.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.96M
YoY Change 20.46%
NET CHANGE
Cash From Operating Activities -11.21M
Cash From Investing Activities
Cash From Financing Activities 10.96M
Net Change In Cash -248.0K
YoY Change -95.61%
FREE CASH FLOW
Cash From Operating Activities -$11.21M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001651407
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27042035
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45095500
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38128
dei Entity Registrant Name
EntityRegistrantName
CHECKPOINT THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2568632
dei Entity Address Address Line1
EntityAddressAddressLine1
95 Sawyer Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 110
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02453
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
652-4500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
CKPT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4703000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4928000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
476000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
450000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
5179000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5378000
CY2024Q3 us-gaap Assets
Assets
5179000
CY2023Q4 us-gaap Assets
Assets
5378000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15635000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15485000
CY2024Q3 ckpt Accounts Payable And Accrued Liabilities To Related Parties Current
AccountsPayableAndAccruedLiabilitiesToRelatedPartiesCurrent
2009000
CY2023Q4 ckpt Accounts Payable And Accrued Liabilities To Related Parties Current
AccountsPayableAndAccruedLiabilitiesToRelatedPartiesCurrent
2815000
CY2024Q3 ckpt Common Stock Warrant Liabilities Current
CommonStockWarrantLiabilitiesCurrent
125000
CY2023Q4 ckpt Common Stock Warrant Liabilities Current
CommonStockWarrantLiabilitiesCurrent
125000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17769000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18425000
CY2024Q3 us-gaap Liabilities
Liabilities
17769000
CY2023Q4 us-gaap Liabilities
Liabilities
18425000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45095500
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27042035
CY2024Q3 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
0
CY2023Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
1492915
CY2023Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
3419000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
329078000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
297864000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-341673000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314333000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-12590000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13047000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5179000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5378000
CY2023Q3 us-gaap Revenues
Revenues
31000
us-gaap Revenues
Revenues
41000
us-gaap Revenues
Revenues
97000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6366000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5496000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19343000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35267000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3358000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2236000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8043000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6809000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
9724000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
7732000
us-gaap Operating Expenses
OperatingExpenses
27386000
us-gaap Operating Expenses
OperatingExpenses
42076000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9724000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7701000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27345000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41979000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
us-gaap Investment Income Interest
InvestmentIncomeInterest
9000
us-gaap Investment Income Interest
InvestmentIncomeInterest
81000
CY2023Q3 ckpt Gain Loss On Common Stock Warrant Liabilities
GainLossOnCommonStockWarrantLiabilities
1970000
ckpt Gain Loss On Common Stock Warrant Liabilities
GainLossOnCommonStockWarrantLiabilities
9179000
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1977000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9260000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9725000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5724000
us-gaap Net Income Loss
NetIncomeLoss
-27340000
us-gaap Net Income Loss
NetIncomeLoss
-32719000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.07
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43151861
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43151861
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19988079
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19988079
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37556863
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37556863
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15842693
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15842693
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-15749000
CY2024Q3 ckpt Stock Issued During Period Value Common Shares For Direct Offering
StockIssuedDuringPeriodValueCommonSharesForDirectOffering
10955000
CY2024Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
318000
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1611000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9725000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-12590000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13047000
ckpt Stock Issued During Period Value Common Shares For Direct Offering
StockIssuedDuringPeriodValueCommonSharesForDirectOffering
23592000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
714000
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
3491000
us-gaap Net Income Loss
NetIncomeLoss
-27340000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-12590000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-23270000
CY2023Q3 ckpt Stock Issued During Period Value Common Shares For Direct Offering
StockIssuedDuringPeriodValueCommonSharesForDirectOffering
9011000
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
251000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
689000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5724000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-19043000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-19483000
ckpt Stock Issued During Period Value Common Shares For Direct Offering
StockIssuedDuringPeriodValueCommonSharesForDirectOffering
30125000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
809000
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2225000
us-gaap Net Income Loss
NetIncomeLoss
-32719000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-19043000
us-gaap Profit Loss
ProfitLoss
-27340000
us-gaap Profit Loss
ProfitLoss
-32719000
us-gaap Share Based Compensation
ShareBasedCompensation
3491000
us-gaap Share Based Compensation
ShareBasedCompensation
2225000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
714000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
809000
ckpt Gain Loss On Common Stock Warrant Liabilities
GainLossOnCommonStockWarrantLiabilities
9179000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
26000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-734000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-42000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
43000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4243000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-806000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
1574000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23924000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40757000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33621000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2301000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3160000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23699000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30461000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-225000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10296000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4928000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12068000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4703000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1772000
us-gaap Stock Issued1
StockIssued1
3419000
us-gaap Stock Issued1
StockIssued1
1885000
ckpt Stock Issued Under Direct Offering Costs Not Paid
StockIssuedUnderDirectOfferingCostsNotPaid
107000
ckpt Stock Issued Under Direct Offering Costs Not Paid
StockIssuedUnderDirectOfferingCostsNotPaid
336000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-341700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
57653135
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25470966
CY2024Q2 ckpt Common Stock Increase In Shares Authorized
CommonStockIncreaseInSharesAuthorized
95000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 ckpt Shelf Registration Statement Maximum Authorized Securities
ShelfRegistrationStatementMaximumAuthorizedSecurities
100000000
CY2023Q4 ckpt Class Of Warrant Or Right Number Of Warrants Issued
ClassOfWarrantOrRightNumberOfWarrantsIssued
110000
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6215354
CY2024Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1611000
CY2023Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
689000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3491000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2225000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7891000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6570000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1102000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1206000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6419000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7123000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
223000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
586000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15635000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15485000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001885-index-headers.html Edgar Link pending
0001410578-24-001885-index.html Edgar Link pending
0001410578-24-001885.txt Edgar Link pending
0001410578-24-001885-xbrl.zip Edgar Link pending
ckpt-20240930.xsd Edgar Link pending
ckpt-20240930x10q.htm Edgar Link pending
ckpt-20240930xex31d1.htm Edgar Link pending
ckpt-20240930xex31d2.htm Edgar Link pending
ckpt-20240930xex32d1.htm Edgar Link pending
ckpt-20240930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
ckpt-20240930_cal.xml Edgar Link unprocessable
ckpt-20240930_def.xml Edgar Link unprocessable
ckpt-20240930_lab.xml Edgar Link unprocessable
ckpt-20240930_pre.xml Edgar Link unprocessable
ckpt-20240930x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending